These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 30876392

  • 1. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
    Santamarina M, Carlson CJ.
    BMC Cardiovasc Disord; 2019 Mar 15; 19(1):60. PubMed ID: 30876392
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies.
    Scheen AJ.
    Diabetes Metab; 2018 Nov 15; 44(5):386-392. PubMed ID: 30126735
    [Abstract] [Full Text] [Related]

  • 3. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
    Maiorino MI, Longo M, Scappaticcio L, Bellastella G, Chiodini P, Esposito K, Giugliano D.
    Cardiovasc Diabetol; 2021 Oct 18; 20(1):210. PubMed ID: 34663316
    [Abstract] [Full Text] [Related]

  • 4. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM, Al Yami MS, Alshibani M, Fallatah SB, Al Khushaym NM, Alsheikh R, Alkhatib N.
    Prim Care Diabetes; 2019 Jun 18; 13(3):204-211. PubMed ID: 30713085
    [Abstract] [Full Text] [Related]

  • 5. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
    Yang CT, Yang CY, Ou HT, Kuo S.
    Cardiovasc Diabetol; 2020 Jun 13; 19(1):83. PubMed ID: 32534570
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ.
    Circ Res; 2018 May 11; 122(10):1439-1459. PubMed ID: 29748368
    [Abstract] [Full Text] [Related]

  • 7. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B, Sonne DP, Metzendorf MI, Richter B.
    Cochrane Database Syst Rev; 2017 May 10; 5(5):CD012204. PubMed ID: 28489279
    [Abstract] [Full Text] [Related]

  • 8. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM, Shih CJ, Chao PW, Chu H, Kuo SC, Lee YJ, Wang SJ, Yang CY, Lin CC, Chen TJ, Tarng DC, Li SY, Chen YT.
    Ann Intern Med; 2015 Nov 03; 163(9):663-72. PubMed ID: 26457538
    [Abstract] [Full Text] [Related]

  • 9. Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.
    Jain R.
    Adv Ther; 2015 Nov 03; 32(11):1065-84. PubMed ID: 26578430
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
    Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK, CARMELINA® investigators.
    Cardiovasc Diabetol; 2018 Mar 14; 17(1):39. PubMed ID: 29540217
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).
    Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Mattheus M, Ryckaert B, Patel S, Johansen OE, Woerle HJ.
    Diab Vasc Dis Res; 2015 May 14; 12(3):164-74. PubMed ID: 25780262
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.
    Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Bluhmki E, Patel S, Johansen OE, Woerle HJ.
    Diab Vasc Dis Res; 2013 Jul 14; 10(4):289-301. PubMed ID: 23449634
    [Abstract] [Full Text] [Related]

  • 16. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A.
    BMJ; 2012 Mar 12; 344():e1369. PubMed ID: 22411919
    [Abstract] [Full Text] [Related]

  • 17. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH.
    Clin Ther; 2016 Jun 12; 38(6):1288-1298. PubMed ID: 27210264
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J, Mehta R, Donnelly R, Idris I.
    Ann Med; 2016 Jun 12; 48(4):224-34. PubMed ID: 26982210
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.